MET and Miyoshi myopathy: However, aptamers are advantageous over antibodies due to their low potential for immunogenicity, efficient tissue penetration, relatively simple synthesis, etc.17 To date, a small number of aptamers have been developed as therapeutic antagonists in MM,18, 19 but none target c‐met.